Opportunities for the development of neuroimmune therapies in addiction

International Review of Neurobiology

Volumn 118, Issue , 2014, Pages 381-401

  Ray, Lara A ^a   Roche, Daniel J O ^a   Heinzerling, Keith ^a   Shoptaw, Steve ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction; Inflammation; Neuroinflammation; Pharmacotherapy; Substance use disorder; Treatment

Indexed keywords

DOXYCYCLINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IBUDILAST; INDOMETACIN; MINOCYCLINE; MN 166; NALTREXONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROLIPRAM; TOLL LIKE RECEPTOR 4; TOPIRAMATE; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; CIGLITAZONE; CLOFIBRATE; NALOXONE; PIOGLITAZONE; ROSIGLITAZONE;

ADDICTION; ALCOHOLISM; ARTICLE; CELL ACTIVATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HIV ASSOCIATED DEMENTIA; HUMAN; IMMUNOTHERAPY; METHAMPHETAMINE DEPENDENCE; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMMUNOLOGY; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE; ANIMAL; IMMUNOLOGY; PROCEDURES; SUBSTANCE-RELATED DISORDERS; ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER; ALCOHOL WITHDRAWAL; ANTIINFLAMMATORY ACTIVITY; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; DISEASE ASSOCIATION; HELP SEEKING BEHAVIOR; HEROIN DEPENDENCE; NEUROMODULATION; NEUROPROTECTION; SUBSTANCE ABUSE;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; SUBSTANCE-RELATED DISORDERS;

EID: 84906777606     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801284-0.00012-9     Document Type: Chapter

References (107)

1. Agrawal R.G., Hewetson A., George C.M., Syapin P.J., Bergeson S.E. Minocycline reduces ethanol drinking. Brain, Behavior, and Immunity 2011, 25(Suppl. 1):S165-S169. 10.1016/j.bbi.2011.03.002.
2. Alfonso-Loeches S., Pascual-Lucas M., Blanco A.M., Sanchez-Vera I., Guerri C. Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. Journal of Neuroscience 2010, 30(24):8285-8295. 10.1523/jneurosci.0976-10.2010.
3. Barak S., Ahmadiantehrani S., Kharazia V., Ron D. Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption. Translational Psychiatry 2011, 419:456-459. 10.1038/tp.2011.57.
4. Barak S., Carnicella S., Yowell Q.V., Ron D. Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: Implications for alcohol reward and seeking. Journal of Neuroscience 2011, 31(27):9885-9894. 10.1523/JNEUROSCI.1750-11.2011.
5. Beardsley P.M., Shelton K.L., Hendrick E., Johnson K.W. The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse. European Journal of Pharmacology 2010, 637(1-3):102-108. 10.1016/j.ejphar.2010.04.010.
6. Becker B.W., Thames A.D., Woo E., Castellon S.A., Hinkin C.H. Longitudinal change in cognitive function and medication adherence in HIV-infected adults. AIDS and Behavior 2011, 15(8):1888-1894. 10.1007/s10461-011-9924-z.
7. Berger J., Moller D.E. The mechanisms of action of PPARs. Annual Review of Medicine 2002, 53(1):409-435.
8. Bhat R., Axtell R., Mitra A., Miranda M., Lock C., Tsien R.W., et al. Inhibitory role for GABA in autoimmune inflammation. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(6):2580-2585. 10.1073/pnas.0915139107.
9. Blanco A.M., Pascual M., Valles S.L., Guerri C. Ethanol-induced iNOS and COX-2 expression in cultured astrocytes via NF-kappa B. Neuroreport 2004, 15(4):681-685.
10. Blanco A.M., Valles S.L., Pascual M., Guerri C. Involvement of TLR4/type I IL-1 receptor signaling in the induction of inflammatory mediators and cell death induced by ethanol in cultured astrocytes. Journal of Immunology 2005, 175(10):6893-6899.
11. Boger H.A., Middaugh L.D., Huang P., Zaman V., Smith A.C., Hoffer B.J., et al. A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Experimental Neurology 2006, 202:336-347. 10.1016/j.expneurol.2006.06.006.
12. Breslin F.J., Johnson B.A., Lynch W.J. Effect of topiramate treatment on ethanol consumption in rats. Psychopharmacology 2010, 207(4):529-534. 10.1007/s00213-009-1683-4.
13. Carey C.L., Woods S.P., Rippeth J.D., Gonzalez R., Heaton R.K., Grant I. Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS and Behavior 2006, 10(2):185-190. 10.1007/s10461-005-9056-4.
14. Carnicella S., Ahmadiantehrani S., Janak P.H., Ron D. GDNF is an endogenous negative regulator of ethanol-mediated reward and of ethanol consumption after a period of abstinence. Alcoholism, Clinical and Experimental Research 2009, 33(6):1012-1024. 10.1111/j.1530-0277.2009.00922.x.
15. Carnicella S., Amamoto R., Ron D. Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor. Alcohol 2009, 43(1):35-43. 10.1016/j.alcohol.2008.12.001.
16. Carnicella S., Kharazia V., Jeanblanc J., Janak P.H., Ron D. GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(23):8114-8119. 10.1073/pnas.0711755105.
17. Carnicella S., Ron D. GDNF-A potential target to treat addiction. Pharmacology & Therapeutics 2009, 122(1):9-18.
18. Cass W.A. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. Journal of Neuroscience 1996, 16(24):8132-8139.
19. Chatterjie N., Alexander G.J., Sechzer J.A., Lieberman K.W. Prevention of cocaine-induced hyperactivity by a naloxone isomer with no opiate antagonist activity. Neurochemical Research 1996, 21(6):691-693.
20. Chatterjie N., Sechzer A., Lieberman K., Alexander G. Dextro-naloxone counteracts amphetamine-induced hyperactivity. Pharmacology, Biochemistry, and Behavior 1998, 59(2):271-274.
21. Cherner M., Letendre S., Heaton R.K., Durelle J., Marquie-Beck J., Gragg B., et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005, 64(8):1343-1347. 10.1212/01.WNL.0000158328.26897.0D.
22. Cho Y., Crichlow G.V., Vermeire J.J., Leng L., Du X., Hodsdon M.E., et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(25):11313-11318. 10.1073/pnas.1002716107.
23. Dean O.M., Data-Franco J., Giorlando F., Berk M. Minocycline: Therapeutic potential in psychiatry. CNS Drugs 2012, 26(5):391-401. 10.2165/11632000-000000000-00000.
24. Fan R., Xu F., Previti M.L., Davis J., Grande A.M., Robinson J.K., et al. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. Journal of Neuroscience 2007, 27(12):3057-3063. 10.1523/JNEUROSCI.4371-06.2007.
25. Fernandez-Lizarbe S., Pascual M., Guerri C. Critical role of TLR4 response in the activation of microglia induced by ethanol. Journal of Immunology 2009, 183(7):4733-4744. 10.4049/jimmunol.0803590.
26. Flora G., Lee Y.W., Nath A., Maragos W., Hennig B., Toborek M. Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: Potential role of reactive oxygen intermediates and lipid peroxidation. Neuromolecular Medicine 2002, 2(1):71-85. 10.1385/NMM:2:1:71.
27. Fujita Y., Ishima T., Kunitachi S., Hagiwara H., Zhang L., Iyo M., et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008, 32(2):336-339. 10.1016/j.pnpbp.2007.08.031.
28. Fujita Y., Kunitachi S., Iyo M., Hashimoto K. The antibiotic minocycline prevents methamphetamine-induced rewarding effects in mice. Pharmacology, Biochemistry, and Behavior 2012, 101(2):303-306. 10.1016/j.pbb.2012.01.005.
29. Ghitza U.E., Zhai H., Wu P., Airavaara M., Shaham Y., Lu L. Role of BDNF and GDNF in drug reward and relapse: A review. Neuroscience & Biobehavioral Reviews 2010, 35(2):157-171.
30. Gibson L.C., Hastings S.F., McPhee I., Clayton R.A., Darroch C.E., Mackenzie A., et al. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. European Journal of Pharmacology 2006, 538(1-3):39-42. 10.1016/j.ejphar.2006.02.053.
31. Gofflot F., Chartoire N., Vasseur L., Heikkinen S., Dembele D., Le Merrer J., et al. Systematic gene expression mapping clusters nuclear receptors according to their function in the brain. Cell 2007, 131(2):405-418.
32. Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. New England Journal of Medicine 2006, 355(6):581-592. 10.1056/NEJMoa055137.
33. Gramage E., Herradon G. Connecting Parkinson's disease and drug addiction: Common players reveal unexpected disease connections and novel therapeutic approaches. Current Pharmaceutical Design 2011, 17(5):449-461. 10.2174/138161211795164103.
34. Hashimoto K., Tsukada H., Nishiyama S., Fukumoto D., Kakiuchi T., Iyo M. Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: A positron emission tomography study in conscious monkeys. Biological Psychiatry 2007, 61(5):577-581. 10.1016/j.biopsych.2006.03.019.
35. Heaton R.K., Clifford D.B., Franklin D.R., Woods S.P., Ake C., Vaida F., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010, 75(23):2087-2096. 10.1212/WNL.0b013e318200d727.
36. Heberlein A., Muschler M., Wilhelm J., Frieling H., Lenz B., Groschl M., et al. BDNF and GDNF serum levels in alcohol-dependent patients during withdrawal. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34(6):1060-1064. 10.1016/j.pnpbp.2010.05.025.
37. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection?. Lancet Neurology 2009, 8(4):382-397. 10.1016/S1474-4422(09)70062-6.
38. Hu W., Lu T., Chen A., Huang Y., Hansen R., Chandler L.J., et al. Inhibition of phosphodiesterase-4 decreases ethanol intake in mice. Psychopharmacology 2011, 218(2):331-339. 10.1007/s00213-011-2290-8.
39. Hutchinson M.R., Northcutt A., Hiranita T., Wang X., Lewis S., Thomas J., et al. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. The Journal of Neuroscience 2012, 32(33):11187-11200.
40. Hutchinson M.R., Shavit Y., Grace P.M., Rice K.C., Maier S.F., Watkins L.R. Exploring the neuroimmunopharmacology of opioids: An integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacological Reviews 2011, 63(3):772-810.
41. Hutchinson M.R., Zhang Y., Brown K., Coats B.D., Shridhar M., Sholar P.W., et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). European Journal of Neuroscience 2008, 28(1):20-29.
42. Johnson B.A., Ait-Daoud N. Topiramate in the new generation of drugs: Efficacy in the treatment of alcoholic patients. Current Pharmaceutical Design 2010, 16(19):2103-2112. 10.2174/138161210791516404.
43. Kalivas P.W., Volkow N.D. The neural basis of addiction: A pathology of motivation and choice. The American Journal of Psychiatry 2005, 162(8):1403-1413. 10.1176/appi.ajp.162.8.1403.
44. Kapadia R., Yi J.-H., Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Frontiers in Bioscience: A Journal and Virtual Library 2008, 13:1813-1826.
45. Kells A.P., Eberling J., Su X., Pivirotto P., Bringas J., Hadaczek P., et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. Journal of Neuroscience 2010, 30(28):9567-9577. 10.1523/JNEUROSCI.0942-10.2010.
46. Ladenheim B., Krasnova I.N., Deng X., Oyler J.M., Polettini A., Moran T.H., et al. Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Molecular Pharmacology 2000, 58(6):1247-1256.
47. Landreth G.E., Heneka M.T. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiology of Aging 2001, 22(6):937-944.
48. LaVoie M.J., Card J.P., Hastings T.G. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Experimental Neurology 2004, 187(1):47-57. 10.1016/j.expneurol.2004.01.010.
49. Letendre S., Paulino A.D., Rockenstein E., Adame A., Crews L., Cherner M., et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. The Journal of Infectious Diseases 2007, 196(3):361-370. 10.1086/519285.
50. Litten R.Z., Egli M., Heilig M., Cui C., Fertig J.B., Ryan M.L., et al. Medications development to treat alcohol dependence: A vision for the next decade. Addiction Biology 2012, 17(3):513-527. 10.1111/j.1369-1600.2012.00454.x.
51. Loftis J.M., Choi D., Hoffman W., Huckans M.S. Methamphetamine causes persistent immune dysregulation: A cross-species, translational report. Neurotoxicity Research 2011, 20(1):59-68. 10.1007/s12640-010-9223-x.
52. Logrip M.L., Zorrilla E.P. Stress history increases alcohol intake in relapse: Relation to phosphodiesterase 10A. Addiction Biology 2012, 17(5):920-933. 10.1111/j.1369-1600.2012.00460.x.
53. Maeda T., Kiguchi N., Fukazawa Y., Yamamoto A., Ozaki M., Kishioka S. Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice. Neuropsychopharmacology 2007, 32(5):1133-1140.
54. Mayfield J., Ferguson L., Harris R.A. Neuroimmune signaling: A key component of alcohol abuse. Current Opinion in Neurobiology 2013, 23(4):513-520.
55. McIver S.R., Muccigrosso M.M., Haydon P.G. The effect of doxycycline on alcohol consumption and sensitivity: Consideration for inducible transgenic mouse models. Experimental Biology and Medicine (Maywood, N.J.) 2012, 237(10):1129-1133. 10.1258/ebm.2012.012029.
56. Melis M., Carta S., Fattore L., Tolu S., Yasar S., Goldberg S.R., et al. Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors. Biological Psychiatry 2010, 68(3):256-264.
57. Melis M., Pillolla G., Luchicchi A., Muntoni A.L., Yasar S., Goldberg S.R., et al. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. The Journal of Neuroscience 2008, 28(51):13985-13994.
58. Miranda R., MacKillop J., Monti P.M., Rohsenow D.J., Tidey J., Gwaltney C., et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: A preliminary laboratory study. Alcoholism, Clinical and Experimental Research 2008, 32(3):489-497. 10.1111/j.1530-0277.2007.00592.x.
59. Mishra M.K., Basu A. Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. Journal of Neurochemistry 2008, 105(5):1582-1595. 10.1111/j.1471-4159.2008.05238.x.
60. Mizuno T., Kurotani T., Komatsu Y., Kawanokuchi J., Kato H., Mitsuma N., et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004, 46(3):404-411. 10.1016/j.neuropharm.2003.09.009.
61. Moallem N., Ray L.A. Quetiapine improves response inhibition in alcohol dependent patients: A placebo-controlled pilot study. Pharmacology, Biochemistry, and Behavior 2012, 100(3):490-493. 10.1016/j.pbb.2011.10.012.
62. Moreno S., Farioli-Vecchioli S., Ceru M. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123(1):131-145.
63. Munzar P., Li H., Nicholson K.L., Wiley J.L., Balster R.L. Enhancement of the discriminative stimulus effects of phencyclidine by the tetracycline antibiotics doxycycline and minocycline in rats. Psychopharmacology 2002, 160(3):331-336. 10.1007/s00213-001-0989-7.
64. Narita M., Miyatake M., Shibasaki M., Shindo K., Nakamura A., Kuzumaki N., et al. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006, 31(11):2476-2488. 10.1038/sj.npp.1301007.
65. Niwa M., Nitta A., Yamada Y., Nakajima A., Saito K., Seishima M., et al. An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization. Biological Psychiatry 2007, 61(7):890-901. 10.1016/j.biopsych.2006.06.016.
66. Page C.P., Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handbook of Experimental Pharmacology 2011, 204:391-414. 10.1007/978-3-642-17969-3_17.
67. Panlilio L.V., Justinova Z., Mascia P., Pistis M., Luchicchi A., Lecca S., et al. Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: Preclinical findings. Neuropsychopharmacology 2012, 37(8):1838-1847.
68. Parsons T.D., Braaten A.J., Hall C.D., Robertson K.R. Better quality of life with neuropsychological improvement on HAART. Health and Quality of Life Outcomes 2006, 4:11. 10.1186/1477-7525-4-11.
69. Pascual M., Blanco A.M., Cauli O., Minarro J., Guerri C. Intermittent ethanol exposure induces inflammatory brain damage and causes long-term behavioural alterations in adolescent rats. European Journal of Neuroscience 2007, 25(2):541-550. 10.1111/j.1460-9568.2006.05298.x.
70. Petrasek J., Bala S., Csak T., Lippai D., Kodys K., Menashy V., et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. Journal of Clinical Investigation 2012, 122(10):3476-3489. 10.1172/JCI60777.
71. Pickworth W.B., Fant R.V., Henningfield J.E. Inhibition of prostaglandin synthesis and effects of ethanol and pentobarbital in humans. Journal of Pharmacology and Experimental Therapeutics 1997, 283(1):274-280.
72. Pistis M., Melis M. From surface to nuclear receptors: The endocannabinoid family extends its assets. Current Medicinal Chemistry 2010, 17(14):1450-1467.
73. Plebani J.G., Ray L.A., Morean M.E., Corbin W.R., MacKillop J., Amlung M.T., et al. Human laboratory paradigms in alcohol research. Alcoholism, Clinical and Experimental Research 2012, 36(6):972-983. 10.1111/j.1530-0277.2011.01704.x.
74. Qin L., Crews F.T. Chronic ethanol increases systemic TLR3 agonist-induced neuroinflammation and neurodegeneration. Journal of Neuroinflammation 2012, 9:130. 10.1186/1742-2094-9-130.
75. Ray L.A., Bujarski S., Chin P.F., Miotto K. Pharmacogenetics of naltrexone in Asian Americans: A randomized placebo-controlled laboratory study. Neuropsychopharmacology 2012, 37(2):445-455. 10.1038/npp.2011.192.
76. Ray L.A., Chin P.F., Heydari A., Miotto K. A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving. Psychopharmacology 2011, 217(3):341-351. 10.1007/s00213-011-2287-3.
77. Ray L.A., Courtney K.E., Ghahremani D.G., Miotto K., Brody A., London E.D. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: Human laboratory findings. Psychopharmacology 2014, 10.1007/s00213-014-3519-0.
78. Ray L.A., Hutchison K.E. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: A double-blind placebo-controlled study. Archives of General Psychiatry 2007, 64(9):1069-1077. 10.1001/archpsyc.64.9.1069.
79. Ray L.A., Hutchison K.E., Tartter M. Application of human laboratory models to pharmacotherapy development for alcohol dependence. Current Pharmaceutical Design 2010, 16(19):2149-2158. 10.2174/138161210791516422.
80. Ray L.A., Lunny K., Bujarski S., Moallem N., Krull J.L., Miotto K. The effects of varenicline on stress-induced and cue-induced craving for cigarettes. Drug and Alcohol Dependence 2013, 131(1-2):136-142. 10.1016/j.drugalcdep.2012.12.015.
81. Ray L.A., Mackillop J., Monti P.M. Subjective responses to alcohol consumption as endophenotypes: Advancing behavioral genetics in etiological and treatment models of alcoholism. Substance Use and Misuse 2010, 45(11):1742-1765. 10.3109/10826084.2010.482427.
82. Ray L.A., Miranda R., MacKillop J., McGeary J., Tidey J.W., Rohsenow D.J., et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Experimental and Clinical Psychopharmacology 2009, 17(2):122-129. 10.1037/a0015700.
83. Rippeth J.D., Heaton R.K., Carey C.L., Marcotte T.D., Moore D.J., Gonzalez R., et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. Journal of the International Neuropsychological Society: JINS 2004, 10(1):1-14. 10.1017/S1355617704101021.
84. Rolan P., Hutchinson M., Johnson K. Ibudilast: A review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opinion on Pharmacotherapy 2009, 10(17):2897-2904. (Review). 10.1517/14656560903426189.
85. Rocha S.M., Cristovão A.C., Campos F.L., Fonseca C.P., Baltazar G. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiology of Disease 2012, 47(3):407-415. 10.1016/j.nbd.2012.04.014.
86. Sailasuta N., Abulseoud O., Harris K.C., Ross B.D. Glial dysfunction in abstinent methamphetamine abusers. Journal of Cerebral Blood Flow and Metabolism 2010, 30(5):950-960. 10.1038/jcbfm.2009.261.
87. Sarruf D.A., Yu F., Nguyen H.T., Williams D.L., Printz R.L., Niswender K.D., et al. Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 2009, 150(2):707-712. 10.1210/en.2008-0899.
88. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., et al. Methamphetamine causes microglial activation in the brains of human abusers. Journal of Neuroscience 2008, 28(22):5756-5761. 10.1523/JNEUROSCI.1179-08.2008.
89. Shavit Y., Wolf G., Goshen I., Livshits D., Yirmiya R. Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain 2005, 115(1-2):50-59. 10.1016/j.pain.2005.02.003.
90. Sidoryk-Wegrzynowicz M., Wegrzynowicz M., Lee E., Bowman A.B., Aschner M. Role of astrocytes in brain function and disease. Toxicologic Pathology 2011, 39(1):115-123. 10.1177/0192623310385254.
91. Silverstein P.S., Shah A., Gupte R., Liu X., Piepho R.W., Kumar S., et al. Methamphetamine toxicity and its implications during HIV-1 infection. Journal of Neurovirology 2011, 17(5):401-415. 10.1007/s13365-011-0043-4.
92. Sofuoglu M., Mooney M., Kosten T., Waters A., Hashimoto K. Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. Psychopharmacology 2011, 213(1):61-68. 10.1007/s00213-010-2014-5.
93. Stopponi S., Somaini L., Cippitelli A., Cannella N., Braconi S., Kallupi M., et al. Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biological Psychiatry 2011, 69(7):642-649.
94. Suzumura A., Ito A., Mizuno T. Phosphodiesterase inhibitors suppress IL-12 production with microglia and T helper 1 development. Multiple Sclerosis 2003, 9(6):574-578.
95. Suzumura A., Ito A., Yoshikawa M., Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Research 1999, 837(1-2):203-212. 10.1016/S0006-8993(99)01666-2.
96. Thomas D.M., Francescutti-Verbeem D.M., Kuhn D.M. Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling. Journal of Neurochemistry 2008, 106(2):696-705. 10.1111/j.1471-4159.2008.05421.x.
97. Thomas D.M., Kuhn D.M. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Research 2005, 1050(1-2):190-198. 10.1016/j.brainres.2005.05.049.
98. Wakita H., Tomimoto H., Akiguchi I., Lin J.X., Ihara M., Ohtani R., et al. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Research 2003, 992(1):53-59. 10.1016/j.brainres.2003.08.028.
99. Wang C., Yang X.M., Zhuo Y.Y., Zhou H., Lin H.B., Cheng Y.F., et al. The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. The International Journal of Neuropsychopharmacology 2012, 15(6):749-766. 10.1017/S1461145711000836.
100. Wen R.T., Zhang M., Qin W.J., Liu Q., Wang W.P., Lawrence A.J., et al. The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats. Alcoholism, Clinical and Experimental Research 2012, 36(12):2157-2167. 10.1111/j.1530-0277.2012.01845.x.
101. Woods J.W., Tanen M., Figueroa D.J., Biswas C., Zycband E., Moller D.E., et al. Localization of PPARδ in murine central nervous system: Expression in oligodendrocytes and neurons. Brain Research 2003, 975(1):10-21.
102. Wu Y., Lousberg E.L., Moldenhauer L.M., Hayball J.D., Coller J.K., Rice K.C., et al. Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. British Journal of Pharmacology 2012, 165(5):1319-1329. 10.1111/j.1476-5381.2011.01572.x.
103. Wu Y., Lousberg E.L., Moldenhauer L.M., Hayball J.D., Robertson S.A., Coller J.K., et al. Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment. Brain, Behavior, and Immunity 2011, 25(Suppl. 1):S155-S164. 10.1016/j.bbi.2011.01.012.
104. Yadav A., Collman R.G. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. Journal of Neuroimmune Pharmacology: The Official Journal of the Society on NeuroImmune Pharmacology 2009, 4(4):430-447. 10.1007/s11481-009-9174-2.
105. Yan Y., Yamada K., Niwa M., Nagai T., Nitta A., Nabeshima T. Enduring vulnerability to reinstatement of methamphetamine-seeking behavior in glial cell line-derived neurotrophic factor mutant mice. The FASEB Journal 2007, 21(9):1994-2004. 10.1096/fj.06-7772com.
106. Yoshimura T., Usui H., Takahashi N., Yoshimi A., Saito S., Aleksic B., et al. Association analysis of the GDNF gene with methamphetamine use disorder in a Japanese population. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35(5):1268-1272. 10.1016/j.pnpbp.2011.04.003.
107. Zalewska-Kaszubska J., Bajer B., Gorska D., Andrzejczak D., Dyr W., Bienkowski P. Effect of repeated treatment with topiramate on voluntary alcohol intake and beta-endorphin plasma level in Warsaw alcohol high-preferring rats. Psychopharmacology 2013, 225(2):275-281. 10.1007/s00213-012-2812-z.